德納維製藥 DVAX 深 滬
已收盤 12-19 16:00:00 美东时间
10.86
-0.010
-0.09%
華盛通- 最 高11.07
- 今 開10.88
- 成交量 396.05万股
- 最 低 10.84
- 昨 收 10.87
- 總市值 12.71亿
- 52周最高 14.63
- 市盈率 靜 53.03
- 換手率 3.39%
- 52周最低 9.20
- 委 比 4.03%
- 總股本 1.17亿
- 歷史最高 32.49
- 量 比 2.76
- 振 幅 2.12%
- 歷史最低 0.98
- 每 手 1
- 風險率 1.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CDC signs off on change in newborn hepatitis b vaccine schedule
The CDC on Tuesday evening formally adopted a change in the newborn vaccine schedule that doesn't recommend all babies born to mothers who test negative for hepatitis b get the shot against the virus....
12-17 12:03
CDC vaccine panel set to debate hepatitis b shots, childhood immunizations
A two-day meeting of the CDC's influential Advisory Committee on Immunization Practices set for December 4-5 will discuss continuing to give newborn babies hepatitis b shots as well as examine the chi...
12-03 02:56
Vaxart, Precigen among biotech gainers after Q3 results
Shares of oral vaccine developer Vaxart (OTC:VXRT) and immunotherapy maker Precigen (PGEN) surged on Friday after the two biotechs posted strong topline beats with their Q3 2025 financials. San Franci...
11-15 03:06
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
Vaxart, Inc. announced a business update and financial results for Q3 2025, including entering into an exclusive license agreement with Dynavax for its COVID-19 oral vaccine candidate, potential proceeds up to $700 million plus royalties. Enrollment in the COVID-19 Phase 2b trial with ~5,400 participants is complete, with topline data expected late 2026. Positive Phase 1 data for the second-generation norovirus vaccine candidate was reported, sho...
11-13 21:05
Dynavax Is Providing FY25 Financial Guidance, Based On Its Current Operating Plan; HEPLISAV-B Net Product Revenue Is Expected In The Range Of $315M-$325M; Adjusted EBITDA Is Expected To Be At Least $80M, An Increase Compared To The Prior Guidance Of At Least $75M
FULL YEAR 2025 FINANCIAL GUIDANCEDynavax is providing full year 2025 financial guidance, based on its current operating plan: HEPLISAV-B net product revenue is expected in the range of $315 to $325 million.Adjusted
11-06 05:03
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
FDA-approved Emrosi (DFD-29), a modified-release minocycline formulation, has demonstrated superior efficacy in treating inflammatory lesions of rosacea in adults compared to both placebo and doxycycline in two Phase 3 clinical trials. Emrosi achieved statistically significant higher Investigator’s Global Assessment (IGA) success rates (62.7%) and greater reductions in inflammatory lesion counts (-19.2) compared to Oracea (39.0%, -14.8) and place...
10-24 12:30
Dynavax Presents Topline Data From Part 1 Of Phase 1/2 Trial For Shingles Vaccine Candidate At IDWeek 2025; Announces Initiation Of Part 2 Of Trial
Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profileNewly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 armsCompany
10-22 04:03
Dynavax Announces Management Restructuring Changes
Dynavax ( ($DVAX) ) has provided an update. On October 15, 2025, Dynavax Techno...
10-16 18:29
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.
09-26 12:08
